Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

BackgroundEnfortumab vedotin (EV) is an antibody-drug conjugate approved for patients with treatment-refractory advanced urothelial carcinoma (aUC), however data on biomarkers of response is lacking.MethodsWe retrospectively identified all aUC patients at our institution who received EV monotherapy...

Full description

Bibliographic Details
Main Authors: Tanya Jindal, Xiaolin Zhu, Rohit Bose, Vipul Kumar, Edward Maldonado, Prianka Deshmukh, Chase Shipp, Stephanie Feng, Michelle S. Johnson, Austin Angelidakis, Daniel Kwon, Hala T. Borno, Ivan de Kouchkovsky, Arpita Desai, Rahul Aggarwal, Lawrence Fong, Eric J. Small, Anthony Wong, Sima Porten, Jonathan Chou, Terence Friedlander, Vadim S. Koshkin
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
urothelial carcinoma
antibody drug conjugate (ADC)
enfortumab vedotin
genetic markers
next generating sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1161089/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1161089/full

Similar Items